Boston Scientific prices €4.25B and $3B notes to fund Penumbra deal
What's the deal? Boston Scientific has priced two senior-note offerings — $3 billion in US dollar-denominated notes and €4.25 billion in euro-denominated notes — to help finance its acquisition of medical device maker Penumbra. The company announced the pricing on November 19, 2026, with both offerings expected to close on December 1.
The details: The USD notes span four tranches maturing between 2029 and 2036, carrying coupons from 5.375% to 5.875%. The euro notes, issued through subsidiary American Medical Systems Europe B.V. and guaranteed by Boston Scientific, run across six tranches maturing from 2028 to 2046.
Why now? Boston Scientific intends to use the net proceeds, alongside short-term borrowings and cash on hand, to fund the cash consideration for the Penumbra acquisition and cover related fees. Any leftover funds go toward general corporate purposes.
What could go wrong? Neither offering is conditioned on the deal closing. If the Penumbra acquisition is not completed by the relevant deadline, most note series — all except the floating-rate notes — face a special mandatory redemption at 101% of principal, plus accrued interest.
The signal: At €4.25 billion, the euro offering ranks among the largest post-IPO debt raises on record for a US health company — in the 96th percentile across more than 1,177 comparable rounds. Boston Scientific is leaning on debt markets to underwrite a sizeable bet on expanding its device portfolio.
Read more: finance.yahoo.com
Image credit: Boston Scientific